RU2448958C2 - Производные азапептидов - Google Patents

Производные азапептидов Download PDF

Info

Publication number
RU2448958C2
RU2448958C2 RU2010100821/04A RU2010100821A RU2448958C2 RU 2448958 C2 RU2448958 C2 RU 2448958C2 RU 2010100821/04 A RU2010100821/04 A RU 2010100821/04A RU 2010100821 A RU2010100821 A RU 2010100821A RU 2448958 C2 RU2448958 C2 RU 2448958C2
Authority
RU
Russia
Prior art keywords
compound
therapeutic agents
pharmaceutically acceptable
inhibitor
administration
Prior art date
Application number
RU2010100821/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2010100821A (ru
Inventor
Скотт Л. ХАРБЕСОН (US)
Скотт Л. Харбесон
Роджер Д. ТУНГ (US)
Роджер Д. Тунг
Original Assignee
Консерт Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Консерт Фармасьютикалз, Инк. filed Critical Консерт Фармасьютикалз, Инк.
Publication of RU2010100821A publication Critical patent/RU2010100821A/ru
Application granted granted Critical
Publication of RU2448958C2 publication Critical patent/RU2448958C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
RU2010100821/04A 2007-06-12 2008-06-12 Производные азапептидов RU2448958C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93420107P 2007-06-12 2007-06-12
US60/934,201 2007-06-12
US6762708P 2008-02-29 2008-02-29
US61/067,627 2008-02-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2012101881/04A Division RU2012101881A (ru) 2007-06-12 2012-01-19 Производные азапептидов

Publications (2)

Publication Number Publication Date
RU2010100821A RU2010100821A (ru) 2011-07-20
RU2448958C2 true RU2448958C2 (ru) 2012-04-27

Family

ID=39730784

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2010100821/04A RU2448958C2 (ru) 2007-06-12 2008-06-12 Производные азапептидов
RU2012101881/04A RU2012101881A (ru) 2007-06-12 2012-01-19 Производные азапептидов

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2012101881/04A RU2012101881A (ru) 2007-06-12 2012-01-19 Производные азапептидов

Country Status (25)

Country Link
US (4) US20090036357A1 (Direct)
EP (3) EP2003120B9 (Direct)
JP (1) JP2010529196A (Direct)
KR (2) KR101185899B1 (Direct)
CN (2) CN102424668A (Direct)
AR (1) AR066972A1 (Direct)
AT (2) ATE447554T1 (Direct)
AU (1) AU2008267048C1 (Direct)
BR (2) BRPI0813911A2 (Direct)
CA (1) CA2692028C (Direct)
CO (1) CO6241121A2 (Direct)
CY (1) CY1109766T1 (Direct)
DE (1) DE602008000255D1 (Direct)
DK (1) DK2003120T3 (Direct)
ES (3) ES2394952T3 (Direct)
HR (1) HRP20100065T1 (Direct)
MX (1) MX2009013565A (Direct)
PL (1) PL2003120T3 (Direct)
PT (1) PT2003120E (Direct)
RS (1) RS51226B (Direct)
RU (2) RU2448958C2 (Direct)
SI (1) SI2003120T1 (Direct)
TW (1) TW200908970A (Direct)
WO (1) WO2008156632A1 (Direct)
ZA (1) ZA200909079B (Direct)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2736941C2 (ru) * 2015-12-02 2020-11-23 Мерк Шарп энд Доум Корп. Фармацевтические композиции, содержащие доравирин, тенофовира дизопроксила фумарат и ламивудин

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103899A1 (en) * 2007-02-23 2008-08-28 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
BRPI0813911A2 (pt) 2007-06-12 2012-02-22 Concert Pharmaceuticals Inc. Composto derivado de azapeptídeos e composição farmacêutica contendo o mesmo
WO2010041241A2 (en) * 2008-10-06 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Hiv-1 integrase derived peptides and compositions
WO2010132663A1 (en) * 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors
WO2010135424A1 (en) * 2009-05-19 2010-11-25 Glaxosmithkline Llc Chemical compounds
ES2600878T3 (es) 2009-12-21 2017-02-13 Janssen Sciences Ireland Uc Implante removible, degradable, para la liberación prolongada de un compuesto activo
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
RS58546B1 (sr) 2011-06-20 2019-05-31 H Lundbeck As Deuterizovani 1-piperazino-3-fenil indani za tretiranje šizofrenije
CN106543073A (zh) * 2015-09-17 2017-03-29 宁波杰尔盛化工有限公司 2-[4-（2-吡啶基）苄基]-肼羧酸叔丁酯的制备方法
MX2018011792A (es) 2016-03-28 2019-07-04 Incyte Corp Compuestos de pirrolotriazina como inhibidores de tyro3, axl y mer (tam).
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
EP3687996B1 (en) 2017-09-27 2021-11-03 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
DK3813800T3 (da) * 2018-06-29 2025-06-02 Incyte Corp Formuleringer af en axl/mer-hæmmer
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
AU2021257341A1 (en) * 2020-04-16 2022-11-17 The Medical College Of Wisconsin, Inc. Aerosolized formulations of HIV protease inhibitors for the treatment of airway reflux
CN115583984A (zh) * 2022-01-11 2023-01-10 嘉兴安谛康生物科技有限公司 氮杂螺类化合物及其制备方法、药物组合物和用途
US20250051375A1 (en) 2023-05-31 2025-02-13 Gilead Sciences, Inc. Anti-hiv compounds
CN116987024A (zh) * 2023-08-01 2023-11-03 浙江荣耀生物科技股份有限公司 一种阿扎那韦中间体的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004106787A (ru) * 2001-08-31 2004-12-10 Бристол-Маерс Сквибб Компани Применение атазанавира в терапии вич-инфекции
WO2006014282A2 (en) * 2004-07-06 2006-02-09 Abbott Laboratories Prodrugs of hiv protease inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196607B (en) 1985-05-15 1988-12-28 Wellcome Found Process for producing dideoxy-nucleosides and pharmaceutics comprising such compounds
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
KR100187990B1 (ko) 1992-12-29 1999-06-01 스티븐 에프. 웨인스톡 레트로바이러스성 프로테아제 억제 화합물 제조용 합성 중간체
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
AU2959397A (en) 1996-05-31 1998-01-05 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9914821D0 (en) 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
DE60001623T2 (de) 1999-12-03 2003-12-18 Pfizer Products Inc., Groton Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
KR100554816B1 (ko) 2001-05-03 2006-02-22 에프. 호프만-라 로슈 아게 비결정질 넬피나비르 메실레이트의 약학 제형
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
ES2274119T3 (es) * 2001-08-31 2007-05-16 Bristol-Myers Squibb Company Uso de atazavir en terapia.
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
EP1599172A4 (en) 2003-02-21 2006-07-26 Jarrow Formulas Inc METHODS FOR THE TREATMENT OF HIV OR MALARIA USING CHLOROQUINE COMBINATIONS AND PROTEASE INHIBITORS
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050148523A1 (en) 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
EP1809247A1 (en) 2004-09-29 2007-07-25 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
RU2403066C2 (ru) 2004-12-03 2010-11-10 Мерк Шарп Энд Домэ Корп Применение атазанавира для улучшения фармакокинетики лекарственных средств, метаболизируемых ugt1a1
WO2007041630A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
CA2661404A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
BRPI0813911A2 (pt) 2007-06-12 2012-02-22 Concert Pharmaceuticals Inc. Composto derivado de azapeptídeos e composição farmacêutica contendo o mesmo
US20090076097A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
WO2010132663A1 (en) 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004106787A (ru) * 2001-08-31 2004-12-10 Бристол-Маерс Сквибб Компани Применение атазанавира в терапии вич-инфекции
WO2006014282A2 (en) * 2004-07-06 2006-02-09 Abbott Laboratories Prodrugs of hiv protease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XU ZHONGMIN et al. "Process Research and Development for an Efficient Synthesis of the HIV Protease Inhibitor BMS-232632" ORGANIC PROCESS RESEARCH AND DEVELOPMENT, 2002, vol.6, no.3, 2002, pages 323-328. ZHANG HUIPING et al. "A facile and efficient synthesis of d3-labelled Reyataz" JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, 2005, vol.48, no.14, pages 1041-1047. CIHLAR et al. "Suppression of HIV-1 Protease Inhibitor Resistance by Phosphonate-mediated Solvent Anchoring" JOURNAL OF MOLECULAR BIOLOGY, 2006, vol.363, no.3, pages 635-647. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2736941C2 (ru) * 2015-12-02 2020-11-23 Мерк Шарп энд Доум Корп. Фармацевтические композиции, содержащие доравирин, тенофовира дизопроксила фумарат и ламивудин

Also Published As

Publication number Publication date
EP2003120B1 (en) 2009-11-04
AU2008267048A1 (en) 2008-12-24
AR066972A1 (es) 2009-09-23
US20110009355A1 (en) 2011-01-13
TW200908970A (en) 2009-03-01
KR20100020033A (ko) 2010-02-19
CY1109766T1 (el) 2014-09-10
CA2692028A1 (en) 2008-12-24
WO2008156632A1 (en) 2008-12-24
DK2003120T3 (da) 2010-03-15
RU2012101881A (ru) 2013-07-27
HRP20100065T1 (hr) 2010-03-31
EP2322509A1 (en) 2011-05-18
US20090036357A1 (en) 2009-02-05
CN102424668A (zh) 2012-04-25
HK1127345A1 (en) 2009-09-25
AU2008267048C1 (en) 2013-01-17
US8258309B2 (en) 2012-09-04
US20120165288A1 (en) 2012-06-28
EP2116532A1 (en) 2009-11-11
ES2394952T3 (es) 2013-02-07
KR101185899B1 (ko) 2012-09-27
ES2356334T3 (es) 2011-04-07
US20130041156A1 (en) 2013-02-14
MX2009013565A (es) 2010-06-02
CN101711237B (zh) 2013-08-07
ATE536343T1 (de) 2011-12-15
CO6241121A2 (es) 2011-01-20
KR20120029480A (ko) 2012-03-26
EP2003120A1 (en) 2008-12-17
RS51226B (sr) 2010-12-31
EP2003120B9 (en) 2010-06-02
BRPI0823520A2 (pt) 2013-12-17
PL2003120T3 (pl) 2010-04-30
RU2010100821A (ru) 2011-07-20
PT2003120E (pt) 2010-02-11
BRPI0813911A2 (pt) 2012-02-22
HK1136576A1 (en) 2010-07-02
DE602008000255D1 (de) 2009-12-17
JP2010529196A (ja) 2010-08-26
EP2116532B1 (en) 2011-12-07
CN101711237A (zh) 2010-05-19
EP2322509B1 (en) 2012-08-22
AU2008267048B2 (en) 2012-05-31
CA2692028C (en) 2013-06-04
US8158805B2 (en) 2012-04-17
ZA200909079B (en) 2011-05-25
ES2395137T3 (es) 2013-02-08
ATE447554T1 (de) 2009-11-15
SI2003120T1 (sl) 2010-03-31

Similar Documents

Publication Publication Date Title
RU2448958C2 (ru) Производные азапептидов
HUT71891A (en) 3-phenylpyrrolidine derivatives and pharmaceutical compositions containing them
US20210380546A1 (en) Vaccine adjuvant
WO2009148600A2 (en) Deuterated lysine-based compounds
US20110257111A1 (en) Hydroxyethlamino Sulfonamide Derivatives
US20130040914A1 (en) Prodrugs of an hiv reverse transcriptase inhibitor
HK1154862A (en) Azapeptide derivatives as hiv protease inhibitors
HK1127345B (en) Azapeptide derivatives as hiv protease inhibitors
HK1136576B (en) Azapeptide derivatives as hiv protease inhibitors
AU2012216511A1 (en) Azapeptide derivatives
WO2010132663A1 (en) Pegylated azapeptide derivatives as hiv protease inhibitors
CN120040538A (zh) 嘧啶并环类化合物及其制法、药物组合物和应用
JP2022504259A (ja) Ｎ－（４－フルオロ－３－（６－（３－メチルピリジン－２－イル）－［１，２，４］トリアゾロ［１，５－ａ］ピリミジン－２－イル）フェニル）－２，４－ジメチルオキサゾール－５－カルボキサミドの固体形態
WO2019070698A1 (en) Novel forms of ibrutinib

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160613